Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indapamide for Progressive Multiple Sclerosis
2026-525260-18-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indapamide in primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS), sponsored by Amsterdam University Medical Center. Planned start Sep 2026; status: authorised.
02
Drugs
indapamide
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2026-525260-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525260-18-00.